Dual-targeted liposomes modified with DA7R and T7 peptides (TfR1-targeting) enhanced tumor delivery of DOX and vincristine, exhibiting improved antitumor effects compared to free drugs [422]. This evidence concerns the gene TFRC and neoplasm.